| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyBiologicalProcess | cellular response to interleukin-1 | 2.49e-04 | 85 | 6 | 2 | GO:0071347 | |
| GeneOntologyBiologicalProcess | negative regulation of mRNA catabolic process | 2.61e-04 | 87 | 6 | 2 | GO:1902373 | |
| GeneOntologyBiologicalProcess | negative regulation of RNA catabolic process | 3.52e-04 | 101 | 6 | 2 | GO:1902369 | |
| GeneOntologyBiologicalProcess | response to interleukin-1 | 4.32e-04 | 112 | 6 | 2 | GO:0070555 | |
| GeneOntologyBiologicalProcess | negative regulation of mRNA metabolic process | 4.56e-04 | 115 | 6 | 2 | GO:1903312 | |
| GeneOntologyBiologicalProcess | nuclear-transcribed mRNA catabolic process | 6.00e-04 | 132 | 6 | 2 | GO:0000956 | |
| GeneOntologyBiologicalProcess | response to calcium ion | 8.90e-04 | 161 | 6 | 2 | GO:0051592 | |
| GeneOntologyBiologicalProcess | mRNA metabolic process | 1.58e-03 | 917 | 6 | 3 | GO:0016071 | |
| GeneOntologyBiologicalProcess | cell-matrix adhesion | 2.47e-03 | 270 | 6 | 2 | GO:0007160 | |
| GeneOntologyBiologicalProcess | regulation of mRNA catabolic process | 3.22e-03 | 309 | 6 | 2 | GO:0061013 | |
| GeneOntologyBiologicalProcess | mRNA catabolic process | 4.66e-03 | 373 | 6 | 2 | GO:0006402 | |
| GeneOntologyBiologicalProcess | cell-substrate adhesion | 5.61e-03 | 410 | 6 | 2 | GO:0031589 | |
| GeneOntologyBiologicalProcess | response to metal ion | 5.74e-03 | 415 | 6 | 2 | GO:0010038 | |
| GeneOntologyBiologicalProcess | negative regulation of catabolic process | 5.82e-03 | 418 | 6 | 2 | GO:0009895 | |
| GeneOntologyBiologicalProcess | RNA catabolic process | 6.21e-03 | 432 | 6 | 2 | GO:0006401 | |
| GeneOntologyBiologicalProcess | regulation of mRNA metabolic process | 6.52e-03 | 443 | 6 | 2 | GO:1903311 | |
| GeneOntologyBiologicalProcess | nucleic acid catabolic process | 7.13e-03 | 464 | 6 | 2 | GO:0141188 | |
| Domain | CARG-binding_factor_N | 8.60e-08 | 2 | 6 | 2 | IPR012956 | |
| Domain | CBFNT | 8.60e-08 | 2 | 6 | 2 | PF08143 | |
| Domain | RRM_1 | 1.80e-03 | 208 | 6 | 2 | PF00076 | |
| Domain | RRM | 1.95e-03 | 217 | 6 | 2 | SM00360 | |
| Domain | RRM_dom | 2.14e-03 | 227 | 6 | 2 | IPR000504 | |
| Domain | RRM | 2.19e-03 | 230 | 6 | 2 | PS50102 | |
| Domain | - | 2.46e-03 | 244 | 6 | 2 | 3.30.70.330 | |
| Domain | Nucleotide-bd_a/b_plait | 2.75e-03 | 258 | 6 | 2 | IPR012677 | |
| Pathway | WP_MRNA_PROCESSING | 7.79e-04 | 126 | 5 | 2 | M39406 | |
| Pathway | WP_MRNA_PROCESSING | 9.58e-03 | 451 | 5 | 2 | MM15946 | |
| Pathway | REACTOME_HEMOSTASIS | 1.51e-02 | 571 | 5 | 2 | MM14472 | |
| Pathway | REACTOME_HEMOSTASIS | 2.10e-02 | 679 | 5 | 2 | M8395 | |
| Pubmed | TERRA transcripts are bound by a complex array of RNA-binding proteins. | 9.33e-09 | 28 | 6 | 3 | 20975687 | |
| Pubmed | Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. | 6.28e-08 | 52 | 6 | 3 | 24591637 | |
| Pubmed | 2.29e-07 | 390 | 6 | 4 | 17643375 | ||
| Pubmed | 3.11e-07 | 421 | 6 | 4 | 34650049 | ||
| Pubmed | 3.33e-07 | 90 | 6 | 3 | 23151878 | ||
| Pubmed | TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence. | 3.39e-07 | 430 | 6 | 4 | 38172120 | |
| Pubmed | 8.15e-07 | 121 | 6 | 3 | 34029587 | ||
| Pubmed | 1.16e-06 | 136 | 6 | 3 | 26979993 | ||
| Pubmed | 1.86e-06 | 159 | 6 | 3 | 22751105 | ||
| Pubmed | 2.35e-06 | 172 | 6 | 3 | 26336360 | ||
| Pubmed | 3.37e-06 | 17 | 6 | 2 | 12388589 | ||
| Pubmed | TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation. | 4.92e-06 | 220 | 6 | 3 | 35785414 | |
| Pubmed | BioID-based Identification of Skp Cullin F-box (SCF)β-TrCP1/2 E3 Ligase Substrates. | 5.34e-06 | 226 | 6 | 3 | 25900982 | |
| Pubmed | 5.72e-06 | 22 | 6 | 2 | 12456657 | ||
| Pubmed | Study of FOXO1-interacting proteins using TurboID-based proximity labeling technology. | 6.63e-06 | 243 | 6 | 3 | 36964488 | |
| Pubmed | 6.72e-06 | 244 | 6 | 3 | 29884807 | ||
| Pubmed | SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9. | 7.94e-06 | 258 | 6 | 3 | 37794589 | |
| Pubmed | 8.12e-06 | 260 | 6 | 3 | 36199071 | ||
| Pubmed | 9.51e-06 | 274 | 6 | 3 | 34244482 | ||
| Pubmed | Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. | 1.08e-05 | 30 | 6 | 2 | 15782174 | |
| Pubmed | Interaction proteomics of the HMGA chromatin architectural factors. | 1.23e-05 | 32 | 6 | 2 | 18850631 | |
| Pubmed | The NANCI-Nkx2.1 gene duplex buffers Nkx2.1 expression to maintain lung development and homeostasis. | 1.23e-05 | 32 | 6 | 2 | 28546511 | |
| Pubmed | 1.56e-05 | 36 | 6 | 2 | 17289661 | ||
| Pubmed | NudCL2 regulates cell migration by stabilizing both myosin-9 and LIS1 with Hsp90. | 1.70e-05 | 333 | 6 | 3 | 32665550 | |
| Pubmed | Systematic analysis of human protein complexes identifies chromosome segregation proteins. | 1.72e-05 | 1155 | 6 | 4 | 20360068 | |
| Pubmed | 1.91e-05 | 346 | 6 | 3 | 25324306 | ||
| Pubmed | Cellular RNA binding proteins NS1-BP and hnRNP K regulate influenza A virus RNA splicing. | 1.93e-05 | 40 | 6 | 2 | 23825951 | |
| Pubmed | 3.15e-05 | 51 | 6 | 2 | 26269332 | ||
| Pubmed | Transcription factor protein interactomes reveal genetic determinants in heart disease. | 3.19e-05 | 411 | 6 | 3 | 35182466 | |
| Pubmed | 3.28e-05 | 52 | 6 | 2 | 26265008 | ||
| Pubmed | 3.53e-05 | 425 | 6 | 3 | 21081503 | ||
| Pubmed | 3.54e-05 | 54 | 6 | 2 | 18495661 | ||
| Pubmed | IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. | 4.08e-05 | 58 | 6 | 2 | 21642987 | |
| Pubmed | 4.73e-05 | 469 | 6 | 3 | 37314180 | ||
| Pubmed | LINKIN, a new transmembrane protein necessary for cell adhesion. | 5.07e-05 | 480 | 6 | 3 | 25437307 | |
| Pubmed | 5.52e-05 | 494 | 6 | 3 | 26831064 | ||
| Pubmed | 7.63e-05 | 551 | 6 | 3 | 34728620 | ||
| Pubmed | 9.43e-05 | 88 | 6 | 2 | 26318153 | ||
| Pubmed | CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality. | 1.01e-04 | 605 | 6 | 3 | 28977666 | |
| Pubmed | Proteomic dissection of the von Hippel-Lindau (VHL) interactome. | 1.17e-04 | 98 | 6 | 2 | 21942715 | |
| Pubmed | 1.26e-04 | 652 | 6 | 3 | 31180492 | ||
| Pubmed | PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. | 1.41e-04 | 678 | 6 | 3 | 30209976 | |
| Pubmed | 1.61e-04 | 115 | 6 | 2 | 20000738 | ||
| Pubmed | 1.63e-04 | 711 | 6 | 3 | 33022573 | ||
| Pubmed | 1.64e-04 | 713 | 6 | 3 | 29802200 | ||
| Pubmed | Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. | 1.65e-04 | 714 | 6 | 3 | 28302793 | |
| Pubmed | 1.72e-04 | 725 | 6 | 3 | 27025967 | ||
| Interaction | DMRT2 interactions | 4.79e-08 | 28 | 6 | 3 | int:DMRT2 | |
| Interaction | TRIM31 interactions | 3.68e-06 | 454 | 6 | 4 | int:TRIM31 | |
| Interaction | SCARNA22 interactions | 3.86e-06 | 118 | 6 | 3 | int:SCARNA22 | |
| Interaction | MCTS1 interactions | 5.05e-06 | 129 | 6 | 3 | int:MCTS1 | |
| Interaction | KHDRBS2 interactions | 5.05e-06 | 129 | 6 | 3 | int:KHDRBS2 | |
| Interaction | MALAT1 interactions | 6.33e-06 | 139 | 6 | 3 | int:MALAT1 | |
| Interaction | IL7R interactions | 6.60e-06 | 141 | 6 | 3 | int:IL7R | |
| Interaction | PYGB interactions | 8.27e-06 | 152 | 6 | 3 | int:PYGB | |
| Interaction | RBM45 interactions | 2.09e-05 | 207 | 6 | 3 | int:RBM45 | |
| Interaction | ERG interactions | 2.61e-05 | 223 | 6 | 3 | int:ERG | |
| Interaction | ATXN2 interactions | 7.10e-05 | 312 | 6 | 3 | int:ATXN2 | |
| Interaction | GLDC interactions | 7.73e-05 | 321 | 6 | 3 | int:GLDC | |
| Interaction | FOXO1 interactions | 9.74e-05 | 347 | 6 | 3 | int:FOXO1 | |
| Interaction | IGF2BP2 interactions | 1.06e-04 | 357 | 6 | 3 | int:IGF2BP2 | |
| Interaction | IFIT2 interactions | 1.48e-04 | 64 | 6 | 2 | int:IFIT2 | |
| Interaction | GCFC2 interactions | 1.48e-04 | 64 | 6 | 2 | int:GCFC2 | |
| Interaction | GATA4 interactions | 1.61e-04 | 411 | 6 | 3 | int:GATA4 | |
| Interaction | NUDCD2 interactions | 1.76e-04 | 424 | 6 | 3 | int:NUDCD2 | |
| Interaction | PTBP2 interactions | 1.87e-04 | 72 | 6 | 2 | int:PTBP2 | |
| Interaction | SNRPC interactions | 1.97e-04 | 440 | 6 | 3 | int:SNRPC | |
| Interaction | IFIT3 interactions | 2.31e-04 | 80 | 6 | 2 | int:IFIT3 | |
| Interaction | DENR interactions | 2.37e-04 | 81 | 6 | 2 | int:DENR | |
| Interaction | FBXW11 interactions | 2.44e-04 | 473 | 6 | 3 | int:FBXW11 | |
| Interaction | SRA1 interactions | 2.49e-04 | 83 | 6 | 2 | int:SRA1 | |
| Interaction | SNRPA interactions | 2.58e-04 | 482 | 6 | 3 | int:SNRPA | |
| Interaction | DROSHA interactions | 2.73e-04 | 87 | 6 | 2 | int:DROSHA | |
| Interaction | IGF2BP1 interactions | 3.01e-04 | 508 | 6 | 3 | int:IGF2BP1 | |
| Interaction | SNRPB interactions | 3.17e-04 | 517 | 6 | 3 | int:SNRPB | |
| Interaction | DHX30 interactions | 3.17e-04 | 517 | 6 | 3 | int:DHX30 | |
| Interaction | UBE2G2 interactions | 3.19e-04 | 94 | 6 | 2 | int:UBE2G2 | |
| Interaction | TARDBP interactions | 3.22e-04 | 520 | 6 | 3 | int:TARDBP | |
| Interaction | COL18A1 interactions | 3.47e-04 | 98 | 6 | 2 | int:COL18A1 | |
| Interaction | HNRNPR interactions | 3.52e-04 | 536 | 6 | 3 | int:HNRNPR | |
| Interaction | ITFG1 interactions | 3.60e-04 | 540 | 6 | 3 | int:ITFG1 | |
| Interaction | NAA50 interactions | 3.75e-04 | 102 | 6 | 2 | int:NAA50 | |
| Interaction | BTF3L4 interactions | 3.90e-04 | 104 | 6 | 2 | int:BTF3L4 | |
| Interaction | RIOK1 interactions | 4.05e-04 | 562 | 6 | 3 | int:RIOK1 | |
| Interaction | ILF2 interactions | 4.67e-04 | 590 | 6 | 3 | int:ILF2 | |
| Interaction | H2AX interactions | 4.74e-04 | 593 | 6 | 3 | int:H2AX | |
| Interaction | HNRNPC interactions | 5.77e-04 | 634 | 6 | 3 | int:HNRNPC | |
| Interaction | SNRNP40 interactions | 5.85e-04 | 637 | 6 | 3 | int:SNRNP40 | |
| Interaction | LOC102724334 interactions | 6.47e-04 | 134 | 6 | 2 | int:LOC102724334 | |
| Interaction | DHX9 interactions | 6.55e-04 | 662 | 6 | 3 | int:DHX9 | |
| Interaction | RC3H2 interactions | 6.70e-04 | 667 | 6 | 3 | int:RC3H2 | |
| Interaction | RC3H1 interactions | 7.00e-04 | 677 | 6 | 3 | int:RC3H1 | |
| Interaction | H2BC15 interactions | 7.46e-04 | 144 | 6 | 2 | int:H2BC15 | |
| Interaction | TOP1 interactions | 7.59e-04 | 696 | 6 | 3 | int:TOP1 | |
| Interaction | HNRNPA1L2 interactions | 8.20e-04 | 151 | 6 | 2 | int:HNRNPA1L2 | |
| Interaction | DDX21 interactions | 8.31e-04 | 718 | 6 | 3 | int:DDX21 | |
| Interaction | SYNCRIP interactions | 8.41e-04 | 721 | 6 | 3 | int:SYNCRIP | |
| Interaction | ZCCHC8 interactions | 8.53e-04 | 154 | 6 | 2 | int:ZCCHC8 | |
| Interaction | HNRNPCL1 interactions | 9.32e-04 | 161 | 6 | 2 | int:HNRNPCL1 | |
| Interaction | YBX1 interactions | 9.51e-04 | 752 | 6 | 3 | int:YBX1 | |
| Interaction | PPM1A interactions | 9.55e-04 | 163 | 6 | 2 | int:PPM1A | |
| Interaction | HNRNPA2B1 interactions | 9.59e-04 | 754 | 6 | 3 | int:HNRNPA2B1 | |
| Interaction | CHD3 interactions | 9.70e-04 | 757 | 6 | 3 | int:CHD3 | |
| Interaction | FUS interactions | 9.70e-04 | 757 | 6 | 3 | int:FUS | |
| Interaction | MKRN1 interactions | 9.78e-04 | 165 | 6 | 2 | int:MKRN1 | |
| Interaction | HEATR3 interactions | 1.01e-03 | 168 | 6 | 2 | int:HEATR3 | |
| Interaction | FGF11 interactions | 1.04e-03 | 170 | 6 | 2 | int:FGF11 | |
| Interaction | BTRC interactions | 1.04e-03 | 775 | 6 | 3 | int:BTRC | |
| Interaction | GRB7 interactions | 1.14e-03 | 178 | 6 | 2 | int:GRB7 | |
| Interaction | IVNS1ABP interactions | 1.16e-03 | 180 | 6 | 2 | int:IVNS1ABP | |
| Interaction | H2BC11 interactions | 1.24e-03 | 186 | 6 | 2 | int:H2BC11 | |
| Interaction | ELAVL2 interactions | 1.27e-03 | 188 | 6 | 2 | int:ELAVL2 | |
| Interaction | NME2 interactions | 1.29e-03 | 190 | 6 | 2 | int:NME2 | |
| Interaction | PABPN1 interactions | 1.32e-03 | 192 | 6 | 2 | int:PABPN1 | |
| Interaction | CUL7 interactions | 1.34e-03 | 845 | 6 | 3 | int:CUL7 | |
| Interaction | FN1 interactions | 1.35e-03 | 848 | 6 | 3 | int:FN1 | |
| Interaction | HNRNPK interactions | 1.37e-03 | 853 | 6 | 3 | int:HNRNPK | |
| Interaction | NSRP1 interactions | 1.39e-03 | 197 | 6 | 2 | int:NSRP1 | |
| Interaction | MEPCE interactions | 1.40e-03 | 859 | 6 | 3 | int:MEPCE | |
| Interaction | RO60 interactions | 1.43e-03 | 200 | 6 | 2 | int:RO60 | |
| Interaction | CUL1 interactions | 1.48e-03 | 876 | 6 | 3 | int:CUL1 | |
| Interaction | ZC3H18 interactions | 1.49e-03 | 877 | 6 | 3 | int:ZC3H18 | |
| Interaction | CAND1 interactions | 1.57e-03 | 894 | 6 | 3 | int:CAND1 | |
| Interaction | ILF3 interactions | 1.58e-03 | 896 | 6 | 3 | int:ILF3 | |
| Interaction | OBSL1 interactions | 1.61e-03 | 902 | 6 | 3 | int:OBSL1 | |
| Interaction | PRMT1 interactions | 1.76e-03 | 929 | 6 | 3 | int:PRMT1 | |
| Interaction | RARA interactions | 1.78e-03 | 223 | 6 | 2 | int:RARA | |
| Interaction | OASL interactions | 1.78e-03 | 223 | 6 | 2 | int:OASL | |
| Interaction | CHD4 interactions | 1.81e-03 | 938 | 6 | 3 | int:CHD4 | |
| Interaction | HNRNPA1 interactions | 1.85e-03 | 945 | 6 | 3 | int:HNRNPA1 | |
| Interaction | STRBP interactions | 1.95e-03 | 234 | 6 | 2 | int:STRBP | |
| Interaction | NGRN interactions | 1.97e-03 | 235 | 6 | 2 | int:NGRN | |
| Interaction | PRC1 interactions | 2.01e-03 | 973 | 6 | 3 | int:PRC1 | |
| Interaction | PRKAR1B interactions | 2.02e-03 | 238 | 6 | 2 | int:PRKAR1B | |
| Interaction | SNRNP70 interactions | 2.08e-03 | 984 | 6 | 3 | int:SNRNP70 | |
| Interaction | HECTD1 interactions | 2.08e-03 | 984 | 6 | 3 | int:HECTD1 | |
| Interaction | AR interactions | 2.13e-03 | 992 | 6 | 3 | int:AR | |
| Interaction | UFL1 interactions | 2.38e-03 | 1031 | 6 | 3 | int:UFL1 | |
| Interaction | RBM39 interactions | 2.45e-03 | 1042 | 6 | 3 | int:RBM39 | |
| GeneFamily | RNA binding motif containing | 1.35e-03 | 213 | 5 | 2 | 725 | |
| ToppCell | TCGA-Thymus-Primary_Tumor-Thymoma-Type_AB-2|TCGA-Thymus / Sample_Type by Project: Shred V9 | 1.41e-04 | 139 | 6 | 2 | 4747adc5578d2b2371a8593e33f8fc98379aed43 | |
| ToppCell | facs-Marrow-T_cells-18m-Lymphocytic-lymphoid_progenitor_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.69e-04 | 152 | 6 | 2 | acfafdb64bd5b0eb7371b04cfef51ed2798e9b30 | |
| ToppCell | facs-Marrow-T_cells-18m-Lymphocytic-common_lymphoid_progenitor_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.69e-04 | 152 | 6 | 2 | 9d6c88ceca0569dbeb12e488acec7fcb7f972f03 | |
| ToppCell | facs-MAT-Fat-24m|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.78e-04 | 156 | 6 | 2 | 7433c6d4eb4d061844d8979c1e648d8ed56e1073 | |
| ToppCell | facs-Heart-RA-18m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-04 | 178 | 6 | 2 | b505e2550860e777535ee95f29c936242fd607f1 | |
| ToppCell | facs-Bladder-nan-24m-Epithelial|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.34e-04 | 179 | 6 | 2 | fc9f44fb81da0d381a5141a95a005e66a0be28cc | |
| ToppCell | facs-Bladder-nan-24m|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.34e-04 | 179 | 6 | 2 | 9152d92bb96e65d43de54e933494f0d08ae02c4f | |
| ToppCell | facs-Bladder-nan-24m-Epithelial-nan|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.44e-04 | 183 | 6 | 2 | 268fc48ffd88e19c9dcd1af32b635256fc915742 | |
| ToppCell | facs-Skin-Anagen|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.60e-04 | 189 | 6 | 2 | adbfc723130079b4caf551f66d2aee86fab1903c | |
| ToppCell | facs-Skin-Anagen-3m|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.63e-04 | 190 | 6 | 2 | 3466cebab16964e94da130d0673fa32e7d90b5ed | |
| ToppCell | facs-Skin-Anagen-3m-Epithelial|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.63e-04 | 190 | 6 | 2 | 888ded899f0513d41bf655896d59ae8ef74e0978 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.69e-04 | 192 | 6 | 2 | 3e1a4cb0d83efd502c8613d41a1692bdda5860ed | |
| ToppCell | myeloid-CD34+_Monoblast|World / Lineage and Cell class | 2.77e-04 | 195 | 6 | 2 | 2065de671988ecade90a7be21af9b0912d49f8fc | |
| ToppCell | 390C-Myeloid-Dendritic-cDC_proliferating_1|Dendritic / Donor, Lineage, Cell class and subclass (all cells) | 2.80e-04 | 196 | 6 | 2 | 36ed1918f70b6f5760bb088b15ce422998055cc7 | |
| ToppCell | myeloid-CD34+_Monoblast|myeloid / Lineage and Cell class | 2.86e-04 | 198 | 6 | 2 | e26b98a8380e693110a97d8e5a353998f8d67c6d | |
| ToppCell | COVID-19_Convalescent-T/NK_proliferative|COVID-19_Convalescent / Disease condition and Cell class | 2.89e-04 | 199 | 6 | 2 | c608d953b852b67a4e36bd63d45f0deec3eefbd9 | |
| ToppCell | megakaryocytic-CD34+_Megakaryoblast|megakaryocytic / Lineage and Cell class | 2.89e-04 | 199 | 6 | 2 | 99a65887d3c8a2cde26693dd74404b101bba9d58 | |
| ToppCell | Megakaryocytic-erythropoietic-Erythro-cells-Basophilic_Erythroblast|Megakaryocytic-erythropoietic / Lineage, cell class and subclass | 2.89e-04 | 199 | 6 | 2 | 6f159c1215439ec22374903124085746fa8da333 | |
| ToppCell | VE|World / Condition, Cell_class and T cell subcluster | 2.91e-04 | 200 | 6 | 2 | 8ae7cb81de3ffac5acdf3466d4b516d80cac95d3 | |
| ToppCell | (5)_Fibroblasts-(5)_Fibroblast-H|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4) | 2.91e-04 | 200 | 6 | 2 | 0ebc54d19873a2b7b6d12b81559cb12abd73b90c | |
| Computational | Neighborhood of ESPL1 | 3.13e-04 | 61 | 5 | 2 | MORF_ESPL1 | |
| Computational | Neighborhood of SMC1L1 | 3.24e-04 | 62 | 5 | 2 | MORF_SMC1L1 | |
| Computational | Neighborhood of CDK2 | 4.37e-04 | 72 | 5 | 2 | MORF_CDK2 | |
| Computational | Neighborhood of UBE2N | 7.60e-04 | 95 | 5 | 2 | MORF_UBE2N | |
| Computational | Neighborhood of PPP2CA | 1.40e-03 | 129 | 5 | 2 | MORF_PPP2CA | |
| Computational | Neighborhood of CTBP1 | 2.35e-03 | 168 | 5 | 2 | MORF_CTBP1 | |
| Computational | Neighborhood of HAT1 | 2.55e-03 | 175 | 5 | 2 | MORF_HAT1 | |
| Computational | Neighborhood of ANP32B | 3.25e-03 | 198 | 5 | 2 | MORF_ANP32B | |
| Computational | Neighborhood of AATF | 3.62e-03 | 209 | 5 | 2 | MORF_AATF | |
| Computational | Neighborhood of XRCC5 | 4.56e-03 | 235 | 5 | 2 | MORF_XRCC5 | |
| Computational | Neighborhood of UBE2I | 4.67e-03 | 238 | 5 | 2 | MORF_UBE2I | |
| Computational | Neighborhood of EIF3S2 | 4.98e-03 | 246 | 5 | 2 | MORF_EIF3S2 | |
| Computational | Neighborhood of HDAC1 | 5.31e-03 | 254 | 5 | 2 | MORF_HDAC1 | |
| Computational | Neighborhood of DEK | 5.72e-03 | 264 | 5 | 2 | MORF_DEK | |
| Computational | Neighborhood of BUB3 | 6.29e-03 | 277 | 5 | 2 | MORF_BUB3 | |
| Computational | Neighborhood of HDAC2 | 6.42e-03 | 280 | 5 | 2 | MORF_HDAC2 | |
| Computational | Neighborhood of GNB1 | 7.58e-03 | 305 | 5 | 2 | MORF_GNB1 | |
| Drug | AC1NRA5C | 8.63e-06 | 174 | 6 | 3 | CID005287709 | |
| Drug | estradiol, USP; Down 200; 0.01uM; MCF7; HG-U133A | 1.27e-05 | 198 | 6 | 3 | 121_DN | |
| Drug | AC1L1B55 | 1.51e-04 | 454 | 6 | 3 | CID000001287 | |
| Drug | Grgds | 1.95e-04 | 83 | 6 | 2 | CID000123811 | |
| Drug | AC1L1AUZ | 6.96e-04 | 157 | 6 | 2 | CID000001160 | |
| Drug | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 7.50e-04 | 163 | 6 | 2 | ctd:D015647 | |
| Drug | DB04780 | 8.15e-04 | 170 | 6 | 2 | CID005459389 | |
| Drug | Lanatoside C [17575-22-3]; Up 200; 4uM; MCF7; HT_HG-U133A | 8.54e-04 | 174 | 6 | 2 | 6048_UP | |
| Drug | Salbutamol [18559-94-9]; Up 200; 16.8uM; PC3; HT_HG-U133A | 9.85e-04 | 187 | 6 | 2 | 3677_UP | |
| Drug | Tolazamide [1156-19-0]; Up 200; 12.8uM; HL60; HT_HG-U133A | 1.05e-03 | 193 | 6 | 2 | 2482_UP | |
| Drug | Omeprazole [73590-58-6]; Up 200; 11.6uM; MCF7; HT_HG-U133A | 1.06e-03 | 194 | 6 | 2 | 4951_UP | |
| Drug | 5213008; Up 200; 18uM; MCF7; HT_HG-U133A_EA | 1.06e-03 | 194 | 6 | 2 | 898_UP | |
| Drug | H-89, Dihydrochloride; Up 200; 0.5uM; PC3; HT_HG-U133A | 1.06e-03 | 194 | 6 | 2 | 6921_UP | |
| Drug | Picrotoxinin [17617-45-7]; Up 200; 13.6uM; PC3; HT_HG-U133A | 1.06e-03 | 194 | 6 | 2 | 4260_UP | |
| Drug | 3-alpha-Hydroxy-5-beta-androstan-17-one [53-42-9]; Up 200; 13.8uM; PC3; HT_HG-U133A | 1.07e-03 | 195 | 6 | 2 | 4298_UP | |
| Drug | Hexylcaine hydrochloride [532-76-3]; Down 200; 13.4uM; HL60; HT_HG-U133A | 1.07e-03 | 195 | 6 | 2 | 2708_DN | |
| Drug | PNU-0230031 [267429-39-0]; Up 200; 10uM; PC3; HT_HG-U133A | 1.08e-03 | 196 | 6 | 2 | 4288_UP | |
| Drug | Acacetin [480-44-4]; Up 200; 14uM; PC3; HT_HG-U133A | 1.08e-03 | 196 | 6 | 2 | 4324_UP | |
| Drug | Amyleine hydrochloride [532-59-2]; Up 200; 14.8uM; PC3; HT_HG-U133A | 1.08e-03 | 196 | 6 | 2 | 4089_UP | |
| Drug | Apomorphine hydrochloride hemihydrate [41372-20-7]; Down 200; 6.4uM; HL60; HG-U133A | 1.08e-03 | 196 | 6 | 2 | 2005_DN | |
| Drug | 0175029-0000 [211245-78-2]; Up 200; 1uM; PC3; HT_HG-U133A | 1.09e-03 | 197 | 6 | 2 | 3694_UP | |
| Drug | Harmine hydrochloride [343-27-1]; Up 200; 16uM; HL60; HG-U133A | 1.09e-03 | 197 | 6 | 2 | 1758_UP | |
| Drug | 1,5-Isoquinolinediol; Up 200; 100uM; HL60; HG-U133A | 1.09e-03 | 197 | 6 | 2 | 543_UP | |
| Drug | Dydrogesterone [152-62-5]; Up 200; 12.8uM; PC3; HT_HG-U133A | 1.09e-03 | 197 | 6 | 2 | 4254_UP | |
| Drug | Levodopa [59-92-7]; Up 200; 20.2uM; HL60; HG-U133A | 1.09e-03 | 197 | 6 | 2 | 1972_UP | |
| Drug | Lynestrenol [52-76-6]; Down 200; 14uM; HL60; HG-U133A | 1.09e-03 | 197 | 6 | 2 | 2037_DN | |
| Drug | valdecoxib; Up 200; 10uM; PC3; HT_HG-U133A | 1.09e-03 | 197 | 6 | 2 | 6378_UP | |
| Drug | (+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Up 200; 11uM; MCF7; HT_HG-U133A | 1.09e-03 | 197 | 6 | 2 | 5009_UP | |
| Drug | Pyrilamine maleate [59-33-6]; Up 200; 10uM; MCF7; HT_HG-U133A | 1.09e-03 | 197 | 6 | 2 | 7223_UP | |
| Drug | Pheniramine maleate [132-20-7]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 1.09e-03 | 197 | 6 | 2 | 1492_DN | |
| Drug | Acacetin [480-44-4]; Up 200; 14uM; PC3; HT_HG-U133A | 1.10e-03 | 198 | 6 | 2 | 3767_UP | |
| Drug | Atropine sulfate monohydrate [5908-99-6]; Up 200; 5.8uM; PC3; HT_HG-U133A | 1.10e-03 | 198 | 6 | 2 | 5865_UP | |
| Drug | Dimaprit dihydrochloride [23256-33-9]; Up 200; 17uM; MCF7; HT_HG-U133A | 1.10e-03 | 198 | 6 | 2 | 6520_UP | |
| Drug | Chlorzoxazone [95-25-0]; Down 200; 23.6uM; MCF7; HT_HG-U133A | 1.10e-03 | 198 | 6 | 2 | 7456_DN | |
| Drug | Isocorydine (+) [475-67-2]; Up 200; 11.8uM; HL60; HG-U133A | 1.10e-03 | 198 | 6 | 2 | 1787_UP | |
| Drug | Butacaine [149-16-6]; Down 200; 13uM; MCF7; HT_HG-U133A | 1.10e-03 | 198 | 6 | 2 | 6225_DN | |
| Drug | Corynanthine hydrochloride [66634-44-4]; Up 200; 10.2uM; MCF7; HT_HG-U133A | 1.10e-03 | 198 | 6 | 2 | 4811_UP | |
| Drug | Seneciphylline [480-81-9]; Up 200; 12uM; MCF7; HT_HG-U133A | 1.10e-03 | 198 | 6 | 2 | 2797_UP | |
| Drug | Buflomedil hydrochloride [35543-24-9]; Up 200; 11.6uM; PC3; HT_HG-U133A | 1.10e-03 | 198 | 6 | 2 | 4258_UP | |
| Drug | Atracurium besylate [64228-81-5]; Down 200; 3.2uM; PC3; HT_HG-U133A | 1.10e-03 | 198 | 6 | 2 | 1824_DN | |
| Drug | Isradipine [75695-93-1]; Up 200; 10.8uM; HL60; HT_HG-U133A | 1.11e-03 | 199 | 6 | 2 | 3129_UP | |
| Drug | nordihydroguaiaretic acid; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 1.11e-03 | 199 | 6 | 2 | 1003_DN | |
| Drug | Progesterone [57-83-0]; Up 200; 12.8uM; MCF7; HT_HG-U133A | 1.11e-03 | 199 | 6 | 2 | 3287_UP | |
| Drug | Thioproperazine dimesylate [2347-80-0]; Up 200; 6.2uM; HL60; HG-U133A | 1.11e-03 | 199 | 6 | 2 | 1390_UP | |
| Drug | Aminophylline [317-34-0]; Up 200; 9.6uM; PC3; HT_HG-U133A | 1.11e-03 | 199 | 6 | 2 | 6295_UP | |
| Drug | Cephalosporanic acid, 7-amino [957-68-6]; Up 200; 14.6uM; MCF7; HT_HG-U133A | 1.11e-03 | 199 | 6 | 2 | 4826_UP | |
| Drug | Medrysone [2668-66-8]; Up 200; 11.6uM; MCF7; HT_HG-U133A | 1.11e-03 | 199 | 6 | 2 | 3603_UP | |
| Drug | Catechin-(+,-) hydrate [7295-85-4]; Up 200; 13.8uM; PC3; HT_HG-U133A | 1.11e-03 | 199 | 6 | 2 | 4255_UP | |
| Drug | PNU-0251126 [267429-19-6]; Up 200; 10uM; PC3; HT_HG-U133A | 1.13e-03 | 200 | 6 | 2 | 3689_UP | |
| Disease | autosomal dominant limb-girdle muscular dystrophy type 3 (implicated_via_orthology) | 3.44e-07 | 6 | 5 | 2 | DOID:0110306 (implicated_via_orthology) | |
| Disease | stroke | 2.34e-04 | 144 | 5 | 2 | EFO_0000712 | |
| Disease | hepatocellular carcinoma (is_marker_for) | 1.02e-03 | 301 | 5 | 2 | DOID:684 (is_marker_for) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| YYLNGGFIIQWNGNY | 751 | P58397 | |
| NPNGRYYWGGQYTWD | 441 | P02675 | |
| RGYDNRAYGQQYWGQ | 666 | Q1KMD3 | |
| YNGLWAYDGWNQLNY | 226 | P82251 | |
| NQGYSNYWNQGYGNY | 291 | Q14103 | |
| NYWNQGYGNYGYNSQ | 296 | Q14103 | |
| QSWNQGYGNYWNQGY | 266 | Q99729 | |
| GYGNYWNQGYGYQQG | 271 | Q99729 |